Medicare
Commentary
Medicare’s Denial Of Coverage To Kidney Patients Could Be Just The Beginning
In September 2018, the Centers for Medicare & Medicaid Services (CMS) sent an email announcing that it would no longer cover Auryxia®. Auryxia® is an FDA approved medicine that treats iron deficiency anemia (anemia) for patients with chronic kidney disease (CKD) but who are not on dialysis. People with CKD ...
Wayne Winegarden
October 22, 2019
Commentary
Mayor Pete’s Medicare for All Who Want It plan as flawed as Medicare for All
Mayor Pete Buttigieg is in hot water with progressives. At last week’s Democratic presidential debate in Ohio, he attacked Senator Elizabeth Warren for refusing to say whether her preferred brand of health reform, Medicare for All, would require middle-class tax hikes. Soon after, a year-old tweet from the South Bend, ...
Sally C. Pipes
October 22, 2019
Commentary
Why we should say no to Medicare for All
This month Sen. Bernie Sanders was released from the hospital after suffering a heart attack. The Vermont senator, a Democratic presidential candidate, used his health scare to renew his call for “Medicare for All,” which he claims will ensure everyone has access to the kind of “great health care” he ...
Sally C. Pipes
October 20, 2019
Commentary
The Senate’s New Drug Bill Is Socialism Lite
House Speaker Nancy Pelosi has a radical new plan to let the federal government set drug prices. In the hopes of combating this bill, many Republicans are holding up Senator Chuck Grassley’s Prescription Drug Pricing Reduction Act as a more moderate alternative. That’s a mistake. While Grassley’s bill isn’t as ...
Sally C. Pipes
October 17, 2019
Commentary
How Long Can Sen. Warren Dodge Questions About Medicare For All?
Presidential hopeful Sen. Elizabeth Warren won’t answer a simple question about the healthcare plan she endorses, Medicare for All. Will it raise taxes on middle-class families? Pressed by moderators at the most recent televised debate last month, she refused to give a straight answer. She parried late-night host Stephen Colbert’s query away. ...
Sally C. Pipes
October 15, 2019
Blog
When Evaluating Socialist Programs, The Path Taken Matters
My last column began a conversation our nation desperately needs to have – forcefully pushing back against the dangerous and misguided myths promoting by proponents of socialism in the U.S. surrounding the supposed socialist success stories in countries like Switzerland, Norway, Sweden, and Denmark. We don’t criticize the policies of ...
Damon Dunn
October 15, 2019
Commentary
Business Leaders Should Crunch the Numbers On Medicare for All
Big business appears to be getting behind Medicare for All. That’s one way to read a new report from the National Business Group on Health. The organization recently asked 147 large employers that provide coverage to over 15.6 million workers and their dependents for their opinions of Medicare for All. ...
Sally C. Pipes
October 9, 2019
Blog
New Survey Results Should Give Lawmakers Pause Before Embracing Single-Payer Health Care
One issue that was pushed on the backburner in this year’s very eventful legislative session was single-payer health care. Surprisingly, even though the Senate actually passed a single payer bill (SB 562) last session, a single-payer bill wasn’t even introduced this legislative session. Now as our attention turns to the ...
Tim Anaya
October 7, 2019
Business & Economics
NEW ISSUE BRIEF: Biosimilars Study Shows Massive State and Taxpayer Savings Possible by Expanding Biosimilars Market
Biosimilars have the opportunity to bring significant savings to state Medicaid programs and consumers with commercial insurance according to a new study released today by Pacific Research Institute. “Every state would experience significant savings in the state Medicaid programs from expanding the use of biosimilars compared to the more expensive ...
Wayne Winegarden
October 2, 2019
Commentary
Across The Atlantic, Nationalized Health Care Is Failing Cancer Patients
The United Kingdom’s National Health Service is failing cancer patients. That’s the grim conclusion of a new study published in the Lancet, a medical journal. Researchers examined five-year survival rates for seven types of cancer in seven “high income” countries. The United Kingdom came in dead last in five of the ...
Sally C. Pipes
September 30, 2019
Medicare’s Denial Of Coverage To Kidney Patients Could Be Just The Beginning
In September 2018, the Centers for Medicare & Medicaid Services (CMS) sent an email announcing that it would no longer cover Auryxia®. Auryxia® is an FDA approved medicine that treats iron deficiency anemia (anemia) for patients with chronic kidney disease (CKD) but who are not on dialysis. People with CKD ...
Mayor Pete’s Medicare for All Who Want It plan as flawed as Medicare for All
Mayor Pete Buttigieg is in hot water with progressives. At last week’s Democratic presidential debate in Ohio, he attacked Senator Elizabeth Warren for refusing to say whether her preferred brand of health reform, Medicare for All, would require middle-class tax hikes. Soon after, a year-old tweet from the South Bend, ...
Why we should say no to Medicare for All
This month Sen. Bernie Sanders was released from the hospital after suffering a heart attack. The Vermont senator, a Democratic presidential candidate, used his health scare to renew his call for “Medicare for All,” which he claims will ensure everyone has access to the kind of “great health care” he ...
The Senate’s New Drug Bill Is Socialism Lite
House Speaker Nancy Pelosi has a radical new plan to let the federal government set drug prices. In the hopes of combating this bill, many Republicans are holding up Senator Chuck Grassley’s Prescription Drug Pricing Reduction Act as a more moderate alternative. That’s a mistake. While Grassley’s bill isn’t as ...
How Long Can Sen. Warren Dodge Questions About Medicare For All?
Presidential hopeful Sen. Elizabeth Warren won’t answer a simple question about the healthcare plan she endorses, Medicare for All. Will it raise taxes on middle-class families? Pressed by moderators at the most recent televised debate last month, she refused to give a straight answer. She parried late-night host Stephen Colbert’s query away. ...
When Evaluating Socialist Programs, The Path Taken Matters
My last column began a conversation our nation desperately needs to have – forcefully pushing back against the dangerous and misguided myths promoting by proponents of socialism in the U.S. surrounding the supposed socialist success stories in countries like Switzerland, Norway, Sweden, and Denmark. We don’t criticize the policies of ...
Business Leaders Should Crunch the Numbers On Medicare for All
Big business appears to be getting behind Medicare for All. That’s one way to read a new report from the National Business Group on Health. The organization recently asked 147 large employers that provide coverage to over 15.6 million workers and their dependents for their opinions of Medicare for All. ...
New Survey Results Should Give Lawmakers Pause Before Embracing Single-Payer Health Care
One issue that was pushed on the backburner in this year’s very eventful legislative session was single-payer health care. Surprisingly, even though the Senate actually passed a single payer bill (SB 562) last session, a single-payer bill wasn’t even introduced this legislative session. Now as our attention turns to the ...
NEW ISSUE BRIEF: Biosimilars Study Shows Massive State and Taxpayer Savings Possible by Expanding Biosimilars Market
Biosimilars have the opportunity to bring significant savings to state Medicaid programs and consumers with commercial insurance according to a new study released today by Pacific Research Institute. “Every state would experience significant savings in the state Medicaid programs from expanding the use of biosimilars compared to the more expensive ...
Across The Atlantic, Nationalized Health Care Is Failing Cancer Patients
The United Kingdom’s National Health Service is failing cancer patients. That’s the grim conclusion of a new study published in the Lancet, a medical journal. Researchers examined five-year survival rates for seven types of cancer in seven “high income” countries. The United Kingdom came in dead last in five of the ...